Group 1 - The overall profitability of the company is under temporary pressure due to market channel adjustments and the expansion of low-margin new businesses, leading to a downward revision of revenue and profit forecasts for the years 2025-2027 [1] - The company's revenue forecast for 2025-2027 has been adjusted from 7.83/8.24/8.62 billion to 7.49/7.90/8.26 billion, and the net profit forecast has been revised from 300/360/430 million to 240/270/320 million [1] - The earnings per share (EPS) forecast for 2025-2027 has been lowered from 0.17/0.20/0.24 to 0.13/0.15/0.18, with a current price-to-earnings (P/E) ratio of 14/12/10 times based on the closing price of HKD 1.96 on February 9, 2026 [1] Group 2 - The domestic milk powder market continues to face challenges, while overseas markets are leading growth, with a significant increase in revenue from overseas markets, particularly in the Middle East, North America, and the CIS [2] - The company expects a decline in domestic goat and cow milk powder business in 2025, but anticipates improvement in 2026 as domestic channels become more streamlined [2] - The company remains optimistic about future market developments and plans to continue expanding in the Middle East and other channels like Walmart in the U.S. to create a clear growth blueprint [2] Group 3 - The company has achieved significant recognition in the milk powder sector, with its brand being recognized as the top-selling nutritional milk powder for three consecutive years [3] - The approval of a new strain of probiotics for infant use marks a significant milestone for the company, enhancing its core technological capabilities and supporting the industrialization of "Chinese bacteria" [3] - The company aims to solidify its market position and expand its growth curve through consumer-centric strategies and research innovation, aspiring to become the most trusted formula milk and nutrition health company globally [3]